Literature DB >> 31246148

Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.

Talal Hilal1, Alanna Maguire2, Heidi E Kosiorek3, Lisa M Rimsza4, Allison C Rosenthal1.   

Abstract

Entities:  

Year:  2019        PMID： 31246148     DOI： 10.1080/10428194.2019.1633637

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

2.  Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.

Authors:  Feili Chen; Diwen Pang; Hanguo Guo; Qiuxiang Ou; Xue Wu; Xinmiao Jiang; Xiaojuan Wei; Sichu Liu; Ling Huang; Zhanli Liang; Dong Zhou; Wenyu Li
Journal:  Cancer Med       Date:  2020-10-17       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.